Key result
The combination of ETA receptor antagonist BQ-123 and ACE inhibitor enalapril synergistically reduced mean arterial pressure (-5.1% vs -2.3% with BQ-123 alone) and renal vascular resistance.
Why the study?
Does the combination of ETA receptor antagonism and ACE inhibition synergistically improve systemic and renal hemodynamics in human subjects?
Population
12 human subjects across two studies (n=6 in each study)
Comparison
Endothelin A receptor antagonist BQ-123 in… vs Placebo, BQ-123 alone, enalapril alone, and…
Design
RCT, randomized, double-blind
Authors
Loading...
ETA antagonism synergizes with ACE inhibition to lower BP and boost natriuresis; extends animal synergy data and supports targeted CKD trials.
RCT (n=12)
double-blind
randomized
Does the combination of ETA receptor antagonism and ACE inhibition synergistically improve systemic and renal hemodynamics in human subjects?
Absolute Event Rate: -5.1% vs -2.3%
p-value: p=< 0.05
The combination of ETA receptor antagonism and ACE inhibition synergistically reduces blood pressure and renal vascular resistance via an ETB receptor-mediated, NO-dependent mechanism.
Goddard et al. (2004) reported an RCT. BQ-123 and enalapril vs. Placebo or BQ-123 alone was evaluated on Mean arterial pressure (mean area under curve) (p=< 0.05). The combination of ETA receptor antagonist BQ-123 and ACE inhibitor enalapril synergistically reduced mean arterial pressure (-5.1% vs -2.3% with BQ-123 alone) and renal vascular resistance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: